Tags » Warner Chilcott

Glenmark Pharmaceuticals entering $130M market with two new generic medicines

Glenmark Pharmaceuticals has been granted final approval by the US Food & Drug Administration for Potassium Chloride Extended-Release Capsules USP, 10 mEq, generic version of Actavis Laboratories’ equivalent drug. 107 more words


Lupin gets a go-ahead to market Blisovi - generic version Warner Chilcott's Loestrin tablets - in U.S.

Pharma Major Lupin Limited (Lupin) has received final approvals for its Blisovi Fe 1/20 Tablets and Blisovi 1.5/30 Tablets from the United States Food and Drug Administration (FDA) to market generic versions of Warner Chilcott’s Loestrin Fe 1/20 Tablets and Loestrin Fe 1.5/30 Tablets. 91 more words


Mylan in patent lawsuit

Mylan N.V. has confirmed that its subsidiaries Mylan Pharmaceuticals Inc., Mylan Laboratories Limited and Mylan Inc., have been sued by Warner Chilcott (US), LLC, Warner Chilcott Company, LLC and Qualicaps Co. 185 more words


Pharma Biggie Hit With $125M Penalty For Illegal Kickbacks To Doctors, Falsified Insurance Forms

A subsidiary of multibillion-dollar international pharmaceuticals company Allergan has agreed to plead guilty to a felony charge of healthcare fraud and pay $125 million to close the books on criminal and civil liability claims tied to the subsidiary’s illegal marketing activities for seven different name-brand prescription drugs. 692 more words

Denosumab increased adherence, BMD in postmenopausal patients.

Patients previously treated with a bisphosphonate who still have a high risk for fracture may benefit from the addition of denosumab, according to data presented at ASBMR 2013. 269 more words


US Stock Chart of the Day. Warner Chilcott (WCRX)

Warner Chilcott (WCRX)

Warner Chilcott is a pharmaceutical company which focuses on women’s healthcare, gastroenterology, dermatology and urology segments of the North American. It develops the therapeutic products for the treatment of diseases related to the dermatology, musculoskeletal, women’s healthcare and general healthcare and community. 146 more words


Actavis buys Warner Chilcott

May 22, 2013 | By Márcio Barra

This Monday, It was confirmed that Actavis, the largest U.S. maker of generic drugs by market value, will acquire Ireland based, specialty pharmaceutical company Warner Chilcott in a stock-for-stock $8.5 billion deal, bigger than the previously reported $5 billion. 291 more words